Evidence map›Paper›PMID 32648540›Full record

ArticleeLife2020

Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma.

Allison N Lau, Zhaoqi Li, Laura V Danai, Anna M Westermark, Alicia M Darnell, Raphael Ferreira, Vasilena Gocheva, Sharanya Sivanand, Evan C Lien, Kiera M Sapp and 9 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Metabolomics ofbioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Tumor organoid-immune cell co-culture systems for precision oncology.Frontiers in cell and developmental biology · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Significance of Malic Enzyme 1 in Cancer: A Review.Current issues in molecular biology · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 3 countries.

Allison N LauKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.ORCID 0000-0003-4250-7355
Zhaoqi LiKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.
Laura V DanaiKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.
Anna M WestermarkKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.
Alicia M DarnellKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.
Raphael FerreiraKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.ORCID 0000-0001-9881-6232
Vasilena GochevaKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.
Sharanya SivanandKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.
Evan C LienKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.
Kiera M SappKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.
Jared R MayersKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.ORCID 0000-0002-8607-1787
Giulia BiffiCold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States.
Christopher R ChinKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.
Shawn M DavidsonKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.
David A TuvesonCold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States.
Tyler JacksKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.
Nicholas J MathesonKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.ORCID 0000-0002-3318-1851
Omer YilmazKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.
Matthew G Vander HeidenKoch Institute for Integrative Cancer Research and the Department of Biology at Massachusetts Institute of Technology, Cambridge, United States.ORCID 0000-0002-6702-4192
Massachusetts Institute of Technology · USUniversity of Cambridge · GBCold Spring Harbor Laboratory · USDana-Farber Cancer Institute · USMassachusetts General Hospital · USPrinceton University · USUniversity of Massachusetts Amherst · US

Funding

Single-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI John Edward Moses · 1987 to 2026
$118.9M
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
PRE-DOCTORAL TRAINING IN THE BIOLOGICAL SCIENCEST32GM007287 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELL, STEPHEN P., KEATING, AMY E · 1985 to 2019
$40.8M
Understanding and Improving Platinum Anticancer DrugsR01CA034992 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YILMAZ, OMER · 1985 to 2018
$6.8M
Understanding the role of metabolism in cancerR35CA242379 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2019 to 2025
$5.8M
The Extracellular Matrix in Tumor Progression and MetastasisU54CA163109 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HYNES, RICHARD O · 2011 to 2015
$3.7M
Analysis of cancer cell metabolism in diverse environmental conditionsR01CA201276 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI VANDER HEIDEN, MATTHEW G., VITKUP, DENNIS · 2016 to 2020
$3.0M
Dietary control of stem cells in physiology and cancerR01CA211184 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YILMAZ, OMER · 2017 to 2021
$2.0M
Regulation of glucose metabolism to allow tumor initiation and growthR01CA168653 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2013 to 2019
$1.9M
Understanding metabolic heterogeneity in pancreatic cancerK99CA234221 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LAU, ALLISON N · 2018 to 2020
$386k
Damon Runyon Cancer Research Foundation DRG-2299-17Damon Runyon Cancer Research Foundation DRG-2367-19EMBO ALTF 1203-2014Howard Hughes Medical InstituteHuman Frontier Science Program LT000195/2015-LMedical Research Council MR/P008801/1MRC CSF MR/P008801/1NCI NIH HHS K99 CA234221NCI NIH HHS P30 CA014051NCI NIH HHS P30 CA045508NCI NIH HHS R01 CA034992NCI NIH HHS R01 CA168653NCI NIH HHS R01 CA201276NCI NIH HHS R01 CA211184NCI NIH HHS R35 CA242379NCI NIH HHS U54 CA163109NHSBT WPA15-02NIGMS NIH HHS T32 GM007287
6 · The paper itself

Abstract

Tumors are composed of many different cell types including cancer cells, fibroblasts, and immune cells. Dissecting functional metabolic differences between cell types within a mixed population can be challenging due to the rapid turnover of metabolites relative to the time needed to isolate cells. To overcome this challenge, we traced isotope-labeled nutrients into macromolecules that turn over more slowly than metabolites. This approach was used to assess differences between cancer cell and fibroblast metabolism in murine pancreatic cancer organoid-fibroblast co-cultures and tumors. Pancreatic cancer cells exhibited increased pyruvate carboxylation relative to fibroblasts, and this flux depended on both pyruvate carboxylase and malic enzyme 1 activity. Consequently, expression of both enzymes in cancer cells was necessary for organoid and tumor growth, demonstrating that dissecting the metabolism of specific cell populations within heterogeneous systems can identify dependencies that may not be evident from studying isolated cells in culture or bulk tissue.

Indexed as

AnimalsCarcinoma, Pancreatic DuctalFemaleMaleMiceMice, Inbred C57BLPancreatic NeoplasmsTumor Microenvironmentcancer biologymalic enzyme 1metabolic heterogeneitymouseorganoid culturepancreatic cancerPDACpyruvate carboxylase

Identifiers

PMID32648540
PMCPMC7406355
OpenAlexW3041700018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.